BioSpace News Archive

STAAR Surgical Company announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024.

Pliant Therapeutics, Inc., a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis.

Bioventus Inc., a global leader in innovations for active healing, announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.

Bormioli Pharma announced a significant increase of 47% in its North American sales for 2023.

Redwire Corporation announced that it is partnering with Eli Lilly and Company on a second spaceflight mission using its in-space pharmaceutical manufacturing platform, PIL-BOX.

Royal Philips, a global leader in health technology, announced an expanded collaboration with Amazon Web Services to address the growing need for secure, scalable digital pathology solutions in the cloud.

Veru Inc. announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss.

electroCore, Inc. announced today that the Company’s Chief Strategy Officer, Joshua Lev, is scheduled to attend the 36th Annual Roth Conference taking place at The Ritz Carlton Laguna Niguel in Dana Point, California on March 17 – 19, 2024.

Outlook Therapeutics, Inc. today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024.

NewAmsterdam Pharma Company N.V. announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.